In a recent decision, the Centers for Medicare and Medicaid Services have declined a proposal to expand Medicare coverage for ...

The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or Wegovy, the Trump administration announced.

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

A rapidly escalating trade war has socked stocks as investors weigh the fallout from President Trump’s tariff barrage.

KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG , Bloomberg News reported on Thursday, ...